Table 1 Pathology of invasive BRCA2 female and male breast tumours and ORs in predicting male BRCA2 mutation carrier status

Total^b

3750

326

 Ductal carcinoma

2693

83.6

253

95.1

Reference

Reference

 Lobular carcinoma

276

8.6

4

1.5

0.15 (0.06–0.41)

0.14 (0.05–0.43)

 Medullary carcinoma

60

1.9

2

0.8

0.35 (0.09–1.46)

0.46 (0.10–2.11)

 Other

193

6.0

7

2.6

0.39 (0.18–0.83)

0.54 (0.24–1.23)

 0–1

560

40.2

44

29.5

Reference

Reference

 2

629

45.1

70

47.0

1.42 (0.95–2.10)

1.97 (1.20–3.23)

 3–4

205

14.7

35

23.5

2.17 (1.37–3.44)

3.55 (1.96–6.44)

 Grade 1

149

5.9

8

3.5

Reference

Reference

 Grade 2

1057

41.7

92

39.8

1.62 (0.77–3.41)

1.88 (0.76–4.67)

 Grade 3

1329

52.4

131

56.7

1.84 (0.88–3.83

2.66 (1.08–6.55)

 Negative

1398

52.4

123

50.2

Reference

Reference

 Positive

1270

47.6

122

49.8

1.09 (0.84–1.43)

1.55 (1.12–2.14)

 Negative

650

22.7

8

3.3

Reference

Reference

 Positive

2211

77.3

236

96.7

8.67 (4.26–17.66)

10.59 (5.15–21.80)

 Negative

892

35.0

30

13.2

Reference

Reference

 Positive

1654

65.0

198

86.8

3.56 (2.41–5.26)

5.04 (3.17–8.04)

 Negative

1404

85.9

126

83.4

Reference

Reference

 Positive

230

14.1

25

16.6

1.21 (0.77–1.90)

1.22 (0.70–2.11)

 ER+ and/or PR+, HER2−

1112

69.8

118

81.9

Reference

Reference

 ER+ and/or PR+, HER2+

182

11.4

22

15.3

1.14 (0.70–1.84)

1.18 (0.65–2.13)

 ER−, PR−, HER2+

40

2.5

2

1.4

0.47 (0.11–1.98)

0.42 (0.09–1.98)

 Triple-negative (ER−, PR−, HER2−)

260

16.3

2

1.4

0.07 (0.02–0.30)

0.05 (0.01–0.22)

 ER+ and/or PR+, HER2− vs. others

0.51 (0.33–0.79)

0.42 (0.25–0.70)